Open an account

Dbv Technologies SA

DBVT · NYSE

$9.75+$0.07 (+0.72%)TodayMarket closed ·
Prev close $9.68

About DBVT

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 125 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

Employees
125
Headquarters
Chatillon, Auvergne-Rhone-Alpes
Listed
Mar 29, 2012
Sector
Health Care
Industry
Biotechnology
Website
dbv-technologies.com

DBVT key statistics

Market cap
552.90M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
437.56K
Volume
258.35K
Open price
$9.68
High today
$9.78
Low today
$9.45
52 Week high
$26.19
52 Week low
$8.63

Dbv Technologies SA (DBVT) at a glance

As of Oct 23, 2026, Dbv Technologies SA (DBVT) shares are priced at $9.75, giving the company a market cap of 552.90M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.45 and $9.78. The current price is 3.2% above the day's low and 0.3% below its high.

Volume so far is 258.35K shares, below the average of 437.56K shares a day.

Over the past year Dbv Technologies SA has ranged from $8.63 to $26.19, and now sits 6% of the way up that range.

Dbv Technologies SA met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.12 per share against an estimate of -$0.101.

The average analyst price target is $29.40, 201.5% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $29.40
Low
$5.57
Now
$9.75
High
$57.92

DBVT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 22.4% on average.

  1. Q4 FY23: reported -$0.11 per share against an estimate of -$0.3333
  2. Q1 FY24: reported -$0.28 per share against an estimate of -$0.3131
  3. Q2 FY24: reported -$0.34 per share against an estimate of -$0.202
  4. Q2 FY25: reported -$0.31 per share against an estimate of -$0.3333
  5. Q3 FY25: reported -$0.24 per share against an estimate of -$0.2525
  6. Q4 FY25: reported -$0.23 per share against an estimate of -$0.1111
  7. Q1 FY26: reported -$0.11 per share against an estimate of -$0.0808
  8. Q2 FY26: reported -$0.12 per share against an estimate of -$0.101

DBVT news

  • Namrata Sen

    How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

  • Gianni di Poce

    The Insider Report: A Tape Fitting for the Holiday

  • Avi Kapoor

    Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • Avi Kapoor

    Crude Oil Rises Over 1%; General Mills Earnings Top Views

  • Vandana Singh

    Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Avi Kapoor

    PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.